Why the study?
An outbreak alert was issued following a surge in acute hemorrhagic conjunctivitis cases along the Kenyan coast caused by coxsackievirus A24 variant.
The development of a whole genome sequencing assay for the coxsackievirus A24 variant will facilitate genomic epidemiology and evolutionary studies of the pathogen responsible for acute hemorrhagic conjunctivitis.
May aid AHC outbreak tracking; leaves open routine clinical adoption pending validation.
<ns3:p>In January 2024, the Kenya Ministry of Health issued an outbreak alert following a surge in acute hemorrhagic conjunctivitis (AHC) cases along the Kenyan coast. Our investigations identified coxsackievirus A24 variant (CA24v) as the causative agent. In this study, we developed a whole genome sequencing assay for CA24v, and used it to recover three near complete genomes from the 2024 AHC outbreak in Kenya. This assay will support studies on CA24v genomic epidemiology and evolution across Kenya and beyond.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Morobe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: